GLP-1R Agonist Treatment for Opioid Use Disorder
NCT06548490 on ClinicalTrials.gov · last registry update 2026-08-28
Recruiting now, toward 200 participants. Due to report 30 April 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Number of participants being abstinent from illicit and nonprescribed opioids. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Milton S. Hershey Medical Center
- Sponsor type
- Other
- Enrollment
- 200
- Started
- 2025-01-27
- Primary completion
- 2027-04-30 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-28 | Reporting date moved | 2027-04 → 2027-04-30 |
Primary outcome
Number of participants being abstinent from illicit and nonprescribed opioids.
Conditions studied
Opioid Use Disorder · Opioid Abuse and Addiction · Narcotic-Related Disorders · Substance-Related Disorders · Chemically-Induced Disorders · Mental Disorder · Opioid
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.